Kala Pharmaceuticals (NASDAQ:KALA)‘s stock had its “buy” rating reissued by Wells Fargo & Co in a report released on Friday.

Other research analysts have also issued reports about the company. BidaskClub upgraded Kala Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, December 29th. Wedbush restated a “buy” rating and issued a $46.00 target price on shares of Kala Pharmaceuticals in a research note on Thursday, November 30th. JPMorgan Chase & Co. set a $35.00 target price on Kala Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, November 19th. Finally, Zacks Investment Research lowered Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $36.80.

Kala Pharmaceuticals (NASDAQ KALA) traded down $0.34 on Friday, hitting $17.33. The stock had a trading volume of 150,500 shares, compared to its average volume of 261,033. Kala Pharmaceuticals has a 12 month low of $13.51 and a 12 month high of $26.75. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.00 and a quick ratio of 11.00.

Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.14). sell-side analysts predict that Kala Pharmaceuticals will post -2.22 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Susquehanna International Group LLP acquired a new position in Kala Pharmaceuticals during the third quarter worth $222,000. Neuberger Berman Group LLC bought a new position in Kala Pharmaceuticals in the third quarter valued at about $1,142,000. Cubist Systematic Strategies LLC bought a new position in Kala Pharmaceuticals during the third quarter worth about $228,000. Crestline Management LP bought a new position in Kala Pharmaceuticals during the third quarter worth about $888,000. Finally, Orbimed Advisors LLC bought a new position in Kala Pharmaceuticals during the third quarter worth about $54,251,000. Institutional investors and hedge funds own 62.96% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/05/kala-pharmaceuticals-kala-buy-rating-reiterated-at-wells-fargo-co.html.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Analyst Recommendations for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.